Syros Pharmaceuticals, Inc. (SYRS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Syros Pharmaceuticals, Inc. (SYRS)
Go deeper and ask any question about SYRS
Company Performance
Current Price
as of Sep 13, 2024$1.95
P/E Ratio
N/A
Market Cap
$52.12M
Description
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerSYRS
- Price$1.95+24.20%
Trading Information
- Market Cap$52.12M
- Float73.66%
- Average Daily Volume (1m)319,878
- Average Daily Volume (3m)293,789
- EPS-$4.30
Company
- Revenue$4.15M
- Rev Growth (1yr)-100.00%
- Net Income-$23.33M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$27.08M
- EV$184.33M
- EV/Revenue44.44
- P/EN/A
- P/S18.46
Documents
SEC Filings
Earnings Calls
Factset Street Account